Genomic Epigenetic Proteomic Metabolomic and Immunologic Characterization of Metastatic Neuroendocrine Tumors Surviving Transarterial Embolotherapy
Recruiting
99 years and younger
All
40 participants needed
1 Location
Brief description of study
mNET is commonly treated with TACE or TACE. mNET cells can survive TACE or TARE ischemic conditions. In this study, we will biopsy mNETs being treated with TACE or TARE prior to treatment, after treatment, and again at recurrence to characterize the metabolic, immunologic, and genetic profile of the cells surviving TACE or TARE.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: TBD
-
Age: - 99 Years
-
Gender: All
Updated on
01 Aug 2024.
Study ID: 825782
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
A copy of the message has been sent to your email
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
